ADA-话题@MedSci

#ADA#

386篇内容 | 2812人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1264723, encodeId=e3e81264e23bd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Blood：ADAMTS13缺陷和补体过度激活协同导致血栓性微血管病, objectType=article, longId=177655, objectId=766e1e765529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=766e1e765529, replyNumber=0, likeNumber=117, createdTime=2019-08-16, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=766e1e765529, moduleTitle=Blood：ADAMTS13缺陷和补体过度激活协同导致血栓性微血管病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=766e1e765529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264722, encodeId=47611264e221c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, objectType=article, longId=175621, objectId=98461e5621b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98461e5621b5, replyNumber=0, likeNumber=86, createdTime=2019-07-18, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98461e5621b5, moduleTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98461e5621b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264721, encodeId=46b11264e2113, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, objectType=article, longId=175230, objectId=0b961e52306e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b961e52306e, replyNumber=0, likeNumber=60, createdTime=2019-07-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b961e52306e, moduleTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b961e52306e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264720, encodeId=f5111264e2090, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Calcif Tissue Int：通过调节TGF-β1诱导的IGF-1和RUNX-2表达，ADAM12参与软骨细胞的分化, objectType=article, longId=174510, objectId=31e21e4510e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31e21e4510e9, replyNumber=0, likeNumber=58, createdTime=2019-07-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31e21e4510e9, moduleTitle=Calcif Tissue Int：通过调节TGF-β1诱导的IGF-1和RUNX-2表达，ADAM12参与软骨细胞的分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31e21e4510e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264719, encodeId=41a41264e19db, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | D2d研究折戟！维生素D未能预防2型糖尿病发生, objectType=article, longId=168603, objectId=8036168603bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8036168603bb, replyNumber=0, likeNumber=86, createdTime=2019-06-18, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8036168603bb, moduleTitle=ADA 2019 | D2d研究折戟！维生素D未能预防2型糖尿病发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8036168603bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264718, encodeId=21301264e1876, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | 糖尿病周围神经病变与哪些因素有关？, objectType=article, longId=168602, objectId=78c416860204, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78c416860204, replyNumber=0, likeNumber=67, createdTime=2019-06-18, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78c416860204, moduleTitle=ADA 2019 | 糖尿病周围神经病变与哪些因素有关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78c416860204)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264717, encodeId=cfa91264e17cd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | 肾脏与心血管并发症有何关系？如何影响糖尿病治疗和预后？, objectType=article, longId=168601, objectId=b8e4168601c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8e4168601c8, replyNumber=0, likeNumber=69, createdTime=2019-06-18, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8e4168601c8, moduleTitle=ADA 2019 | 肾脏与心血管并发症有何关系？如何影响糖尿病治疗和预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8e4168601c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264716, encodeId=f3431264e1668, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Lance-Adams综合征病例报道1例, objectType=article, longId=168359, objectId=7cb316835996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cb316835996, replyNumber=0, likeNumber=63, createdTime=2019-06-15, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cb316835996, moduleTitle=Lance-Adams综合征病例报道1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cb316835996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, objectType=article, longId=168239, objectId=cddc168239ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cddc168239ad, replyNumber=0, likeNumber=56, createdTime=2019-06-14, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cddc168239ad, moduleTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cddc168239ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264714, encodeId=fc141264e147b, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | 打破认知界限，班廷奖获得者介绍二甲双胍改善代谢新机制, objectType=article, longId=168181, objectId=51b716818186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51b716818186, replyNumber=0, likeNumber=83, createdTime=2019-06-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51b716818186, moduleTitle=ADA 2019 | 打破认知界限，班廷奖获得者介绍二甲双胍改善代谢新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51b716818186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264713, encodeId=6ba11264e130b, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | FPG GOAL研究首次揭示：T2DM患者更佳空腹血糖目标为6.1 mmol/L, objectType=article, longId=168178, objectId=6f871681e881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f871681e881, replyNumber=0, likeNumber=74, createdTime=2019-06-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f871681e881, moduleTitle=ADA 2019 | FPG GOAL研究首次揭示：T2DM患者更佳空腹血糖目标为6.1 mmol/L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f871681e881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264712, encodeId=e3851264e1219, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | 8周内减重8%+长期维持，这么做能有效阻止糖尿病前期发展为糖尿病, objectType=article, longId=168172, objectId=bd691681e236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd691681e236, replyNumber=0, likeNumber=65, createdTime=2019-06-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd691681e236, moduleTitle=ADA 2019 | 8周内减重8%+长期维持，这么做能有效阻止糖尿病前期发展为糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd691681e236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264711, encodeId=242f1264e1149, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019 | 肥胖研究有多火？ADA杰出科学成就奖得主就是因为这个获奖, objectType=article, longId=168171, objectId=6cd41681e19e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd41681e19e, replyNumber=0, likeNumber=95, createdTime=2019-06-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd41681e19e, moduleTitle=ADA 2019 | 肥胖研究有多火？ADA杰出科学成就奖得主就是因为这个获奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd41681e19e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264710, encodeId=f9a71264e109b, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=赛诺菲：“CDS-ADA国际学术交流项目”启动, objectType=article, longId=168067, objectId=726b16806e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=726b16806e94, replyNumber=0, likeNumber=56, createdTime=2019-06-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=726b16806e94, moduleTitle=赛诺菲：“CDS-ADA国际学术交流项目”启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=726b16806e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264709, encodeId=9dd31264e09cc, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, objectType=article, longId=168050, objectId=2d6716805018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6716805018, replyNumber=0, likeNumber=79, createdTime=2019-06-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6716805018, moduleTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6716805018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264708, encodeId=a1a01264e08e7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=2019 ADA：使用免疫疗法CD3单抗PRV-031可延迟1型糖尿病发病, objectType=article, longId=168047, objectId=099f16804ea5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099f16804ea5, replyNumber=0, likeNumber=68, createdTime=2019-06-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099f16804ea5, moduleTitle=2019 ADA：使用免疫疗法CD3单抗PRV-031可延迟1型糖尿病发病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099f16804ea5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264707, encodeId=7c031264e07b1, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=战胜糖尿病，靠吃也能行！ADA公布更佳吃饭时间和次序！, objectType=article, longId=168015, objectId=6a58168015ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a58168015ac, replyNumber=0, likeNumber=64, createdTime=2019-06-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a58168015ac, moduleTitle=战胜糖尿病，靠吃也能行！ADA公布更佳吃饭时间和次序！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a58168015ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264706, encodeId=54091264e0625, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, objectType=article, longId=167983, objectId=85e516e98361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e516e98361, replyNumber=0, likeNumber=75, createdTime=2019-06-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e516e98361, moduleTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e516e98361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264705, encodeId=a9d21264e0524, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, objectType=article, longId=167971, objectId=033116e97107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=033116e97107, replyNumber=0, likeNumber=50, createdTime=2019-06-11, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=033116e97107, moduleTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=033116e97107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264704, encodeId=166a1264e0410, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=62, createdTime=2019-06-11, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ADA

2020-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Blood：ADAMTS13缺陷和补体过度激活协同导致血栓性微血管病

2019-08-16

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂

2019-07-18

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验

2019-07-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Calcif Tissue Int：通过调节TGF-β1诱导的IGF-1和RUNX-2表达，ADAM12参与软骨细胞的分化

2019-07-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | D2d研究折戟！维生素D未能预防2型糖尿病发生

2019-06-18

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | 糖尿病周围神经病变与哪些因素有关？

2019-06-18

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | 肾脏与心血管并发症有何关系？如何影响糖尿病治疗和预后？

2019-06-18

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Lance-Adams综合征病例报道1例

2019-06-15

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控

2019-06-14

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | 打破认知界限，班廷奖获得者介绍二甲双胍改善代谢新机制

2019-06-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | FPG GOAL研究首次揭示：T2DM患者更佳空腹血糖目标为6.1 mmol/L

2019-06-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | 8周内减重8%+长期维持，这么做能有效阻止糖尿病前期发展为糖尿病

2019-06-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019 | 肥胖研究有多火？ADA杰出科学成就奖得主就是因为这个获奖

2019-06-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

赛诺菲：“CDS-ADA国际学术交流项目”启动

2019-06-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

2019-06-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

2019 ADA：使用免疫疗法CD3单抗PRV-031可延迟1型糖尿病发病

2019-06-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

战胜糖尿病，靠吃也能行！ADA公布更佳吃饭时间和次序！

2019-06-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平

2019-06-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人

2019-06-11

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力

2019-06-11

科室
- - 订阅+
  - 更多科室
工具
服务